cosyntropin and Joint-Diseases

44 patients with acute irritations of degenerative articular diseases and 66 patients with soft tissue rheumatism were treated with Synacthen Depot (tetracosactide hexacetate 1 mg/ml). During the first three days of treatment the patients received an average of 2 ampoulbs Synacthen Depot, then treatment was continued at 3-4 day intervals. In the degenerative joint disease group 86.4% and 89.4% in the group with soft tissue rheumatism became free of complaints or improved with the ACTH treatment. Most of the patients with degenerative joint diseases needed a 4 week treatment; 1/3 of the patients with soft tissue rheumatism were already free of complai

Topics: Acute Disease; Adrenocorticotropic Hormone; Adult; Aged; Arthritis, Rheumatoid; Cosyntropin; Delayed-Action Preparations; Drug Evaluation; Female; Fibromyalgia; Hip Joint; Humans; Joint Diseases; Knee Joint; Male; Middle Aged; Rheumatic Diseases; Spondylitis